Infuzion System – a proven method of transporting vitamin-rich hyaluronic acid

The method to treat with medical substances using iontophoresis became popular during the beginning of the 20th century. It was Stephen Leduc (1853-1939) who introduced the term ion therapy and created the process.

Iontophoresis

Iontophoresis is a direct electrical current of ions in soluble salts that enter the body’s tissue for therapeutic purposes. It is a technique for improving the absorption of drugs into the skin’s tissues.

Transdermal iontophoresis is transporting molecules between 10 and 100 μm into the skin. The path goes through hair follicles, sweat and secretion glands.

The first use of drug delivery with electric current occurred in the mid 19th century. Major progress was made during this time, especially by Benjamin Ward Richardson (1828-1896). Hermann Munk (1839-1912), William James Morton (1846-1920), Stephen Leduc (1853-1939) and Fritz Frankenhauser (born 1868).

Electrically- assisted transdermal drug deliveries

Today, researchers talk about “electrically- assisted transdermal drug deliveries”. This technique never became popular but always proved useful to some extent as it solved specific problems with drug delivery into the body.

Thirty years ago, the first transdermal drug delivery was introduced in the United States, which made a historic breakthrough. This means that medical formulations could be delivered safely and conveniently through the skin. Nevertheless, the success of transdermal deliveries has developed slowly. But with Infuzion’s new technology, transdermal hyaluronic acid and vitamin delivery seem to have gone forward. The effect is similar to an injection with a skin filler or mesotherapy.

Infuzion System

Infuzion System is a patent where, among other things, metal is replaced with a specialized ceramic to avoid burns that could occur in treatments  before.

Even passive transdermal techniques like patches are growing in popularity. This is due to the size of molecules, e.g. proteins and peptides. Infuzion’s research has led to a better understanding of skin physiology and increased understanding of the transport properties of hyaluronic acid and vitamins.

• Passive – In passive transdermal systems, the drug spreads through the skin through the osmosis process. It can act locally or penetrate the capillaries. This technique is only effective with small molecules, such as in nicotine patches, i.e., nicotine has a molecular weight of 162 Daltons versus 5,808 for insulin.

• Active – Active transdermal systems such as Infuzion use a physical force to facilitate the movement of drug molecules through the skin. By using an applied force (Infuzion electrical current), active transdermal products can deliver hyaluronic acid and vitamins plus other large molecular formulations through the skin into the bloodstream at the same rate as microneedles and insulin pumps.

CONCLUSION

Infuzion Systems’ new technology will take over the ever-increasing invasive anti-aging treatments such as fillers and botulinum toxin type A. in the near future the interest for Infuzion will grow among a large number of transdermal drug delivery systems.

REFERENCES

1. Guy RH, Hadgraft J. Rate control in transdermal drug delivery. Int J Pharm. 1992;82:R1–6.
2. Bouwstra JA, De Vries MA, Gooris GS, Bras W, Brussee J, Ponec M. Thermodynamic and structural aspects of the skin barrier. J Control Release. 1991;15:209–20.
3. Elias PM. Epidermal barrier function: Intercellular lamellar lipid structures, origin, composition and metabolism. J Control Release. 1991;15:199–208.
4. Schnetz E, Fartasch M. Microdialysis for the evaluation of penetration through the human skin barrier: A promising tool for future research. Eur J Pharm Sci. 1991;12:165–74. [PubMed]
5. Singh J, Bahtia KS. Topical iontophoretic drug delivery, Pathways, principles, factors and skin irritation. Med Res Rev. 1996;16:285–96. [PubMed]
6. Cullander C. What are the pathways of iontophoretic current flow through mammalian skin? Adv Drug Del Rev. 1992;9:119–35.
7. Riviere JE, Heit MC. Electrically-assisted transdermal drug delivery. Pharm Res. 1997;14:687–97. [PubMed]
8. Abramson HA, Gorin HH. Skin reactions, IX the electrophoretic demonstration of the patient pores of the living human skin, its relation to the charge of the skin. J Phys Chem. 1940;44:1094–102.
9. Grimnes S. Pathways of ionic flow through human skin in vivo. Acta Derm Venereol. 1984;64:93–8. [PubMed]
10. Burnette RR, Marrero D. Comparision between the iontophoretic and passive transport of thyrotropin releasing hormone across existed nude mouse skin. J Pharm Sci. 1986;75:738–43. [PubMed]
11. Del Terzo S, Bhel CR, Nash RA. Iontophoretic transport of a homologues series of ionized and nonionized model compounds; Influence of Hydrophobicity and mechanistric interpretation. Pharm Res. 1989;6:85–90. [PubMed]
12. Burettee RR, Ongipipattankul B. Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci. 1988;77:132–7. [PubMed]
13. Turner NG, Guy R. Iontophoretic transport pathways, dependence on penetrant physiochemical properties. J Pharm Sci. 1997;86:1385–9. [PubMed]
14. Deagle WR. Iontophoresis dis pain blocker, U.S. patient No. US2003100884, acc. 2003. May 29,
15. Riviere JE, Sage B, Williams PL. Effects of vasoactive drugs on transdermal lidocaine iontophoresis. J Pharm Sci. 1991;80:615–50. [PubMed]
16. Riviere JE, Monteiro NA, Inman AO. Determination of lidocaine concerntrations in skin after transdermal iontophoresis: Effects of vasoactive drugs. Pharm Res. 1992;9:211–4. [PubMed]
17. Pikal MJ, Shah S. Transport mechanisms in iontophoresis II. Electroosmotic flow and transference number measurement for hairless mouse skin. Pharm Res. 1990;7:313–21. [PubMed]
18. Pikal MJ. Transport mechanisms in iontophoresis, I. A theoretical model for the effect of electroosmotic flow on flux enhancement in transdermal iontophoresis. Pharm Res. 1990;7:118–26. [PubMed]
19. Pikal MJ. The role of electroosmosic flow in transdermal iontophoresis. Adv Drug Del Rev. 2001;46:281–305. [PubMed]
20. Uitto OD, White S. Electrosmotic pore transport in human skin. Pharm Res. 2003;20:646–52. [PubMed]
21. Pikal MJ. The role of electroosmosic flow in transdermal iontophoresis. Adv Drug Del Rev. 1992;9:201–37.
22. Inada H, Ghanem AH, Higuchi WI. Studies on the effects of applied voltage and duration on human epidermal membrane alteration/recovery and the resultant effects upon iontophoresis. Pharm Res. 1994;11:687–97. [PubMed]
23. Panchagula R, Pillai O, Nair VB, Ramanrao P. Transdermal iontophoresis revisited. Curr Opin Chem Boil. 2000;4:468–73. [PubMed]
24. Marro D, Kalia YN, Delgado-Charro MB, Guy R. Contributions of electromigration and electroosmosis to iontophoretic drug delivery. Pharm Res. 2001;18:1701–8. [PubMed]
25. Maloney JM. Local anesthesia obtained via iontophoresis as an aid to shave biopsy. Arch Dermatol. 1992;128:331–3. [PubMed]
26. Schmidt JM, Binder M, Maicheiner W, Bielglmayer C. New treatment of atrophic acne scars by iontophoresis with estriol and tretinoin. Int J Dermatol. 1995;34:53–7. [PubMed]
27. Sloan JB, Soltani K. Iontophoresis in dermatology. J Am Acard Dermatol. 1986;5:671–84. [PubMed]
28. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23:545–9. [PubMed]
29. Gibson LE. Iontophorestic sweat test for cyctic fibrosis, technical details. Pediatrics. 1967;39:465–9. [PubMed]
30. Webster HL, Barlow WK. New approach to cystic fibrosis diagnosis by use of an improved sweat-induction/collection system and osmometry. Clin Chem. 1981;27:385–7. [PubMed]
31. Panus PC, Campbell J, Kulkarni SB, Herrick R, Ravis WR, Banga AK. Transdermal iontophoretic delivery of ketoprofen through human cadaver skin and in humans. J Control Release. 1997;44:113–21.
32. Ashburn MA, Streisand J, Zhang J, Love G, Rowin M, Niu S, et al. The iontophoresis of fentanyl citrate in humans. Anesthesiology. 1995;82:1146–53. [PubMed]
33. Chein YW, Siddique O, Shi WM, Lelawongs P, Liu JC. Direct current intophoretictransdernal delivery of peptide and protein drugs. J Pharm Sci. 1989;78:376–83. [PubMed]
34. Stepen RL, Petelenz TJ, Jacobsen SC. Potential novel methods for insulin administration: I Iontophoresis. Biomed Biochem Acta. 1984;43:553–8. [PubMed]
35. Pillai O, Borkute SD, Sivaprasad N, Panchagnula R. Transdermal iontophoresis of insulin II: Physiochemical considerations. Int J Pharm. 2003;254:271–80. [PubMed]
36. Pillai O, Nair V, Panchagnula R. Transdermal iontophoresis of insulin IV: Influence of chemical enhancers. Int J Pharm. 2004;269:109–20. [PubMed]
37. Pillai O, Panchagnula R. Transdermal iontophoresis of insulin V: Efeect of terpenes. J Controlled Release. 2003;88:287–96. [PubMed]
38. Rastogi SK, Singh J. Transepidermal transport enhancement of insulin by lipid extraction and iontophoresis. Pharm Res. 2002;19:427–33. [PubMed]
39. Fang JY, Hung CF, Wong WW. Skin Pharmacol Physiol. 2006;19:28–37. [PubMed]
40. Abramowitz D, Neoussikine B. Treatment by Ion Transfer. New York: Grune and Stratton; 1946. p. 87.
41. Schriber WJ, editor. A manual of electrotherapy. 4th ed. Philadelphia: Lea and Febiger; 1975. pp. 125–31.
42. Bumette RR, Ongpipattanakul B. Charecterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci. 1988;77:132–43. [PubMed]
43. Siddiqui O, Roberts MS, Polock AZ. The effect of iontophoresis and vehicle pH on the in-vitro permeation of lignocaine through human stratum corneum. J Pharm Pharmacol. 1985;37:732–5. [PubMed]
44. Abramson HA, Alley A. Mechanisms of histamine iontophoresis from aqueous media. Arch Phys Ther. 1937;18:327.
45. Chien YW, Siddiqui O, Shi W, Lelawongs P, Liu JC. Direct current iontophoretic Transdermal delivery of peptides and protein drugs. J Pharm Sci. 1989;78:377. [PubMed]
46. Gangarosa LP, Park NH, Fong BC, Scott DF, Hill JM. Conductivity of drugs used for iontophoresis. J Pharm Sci. 1978;67:1439–43. [PubMed]
47. Singh P, Maibach HI. Iontophoresis in drug delivery; Basic principles and applications. Crit Rev Ther Drug Car Sys. 1994;11:161. [PubMed]